# Anticoagulation

Madeleine Turcotte

---

<table border="1">
  <tr>
    <th>Agent</th>
    <th>Treatment Dose</th>
    <th>Renal Dose</th>
    <th>Prophylaxis</th>
    <th>Monitoring</th>
    <th>Hold prior to procedure</th>
  </tr>
  <tr>
    <td>Unfractionated heparin</td>
    <td>80 U/kg bolus, then 18 U/kg/hr</td>
    <td>No change necessary</td>
    <td>5000 U q8h</td>
    <td>PTT (automatic in order set)</td>
    <td>6 hours</td>
  </tr>
  <tr>
    <td>Enoxaparin (Lovenox)</td>
    <td>1 mg/kg q12h<br>or<br>30 mg BID</td>
    <td>1 mg/kg daily</td>
    <td>40 mg daily</td>
    <td>LMWH level (anti-Xa level)<br>Best checked 4 h after 4th dose</td>
    <td>12 hours</td>
  </tr>
  <tr>
    <td>Warfarin (Coumadin)</td>
    <td>Start 2-5mg daily and monitor INR<br>Can consult Pharmacy</td>
    <td>No change necessary</td>
    <td>N/A</td>
    <td>PT/INR<br>Use Chromogenic Factor X assay if pt has APLS</td>
    <td>Several days (Goal INR <1.5)</td>
  </tr>
  <tr>
    <td>Dabigatran (Pradaxa)</td>
    <td>After 5 days of a parenteral AC, 150 mg BID</td>
    <td>Avoid use</td>
    <td>N/A</td>
    <td>Can test drug level if concerned</td>
    <td>At least 48hrs</td>
  </tr>
  <tr>
    <td>Rivaroxaban (Xarelto)</td>
    <td>15 mg BID x21 d then 20 mg daily</td>
    <td>Avoid use in CrCl<30</td>
    <td>10mg QD</td>
    <td></td>
    <td>At least 48hrs</td>
  </tr>
  <tr>
    <td>Apixaban (Eliquis)</td>
    <td>10mg BID x7d, then 5mg BID</td>
    <td>VTE: No adjustment</td>
    <td>2.5 mg BID</td>
    <td>>A Fib: 2.5mg BID, if 2 of the following: Cr 1.5, Age > 80, Weight < 60kg</td>
    <td>At least 48hrs</td>
  </tr>
  <tr>
    <td>Edoxaban (Savaysa)</td>
    <td>After 5 days of a parenteral AC, 60 mg daily</td>
    <td>30 mg for CrCl 15-50<br>Avoid if CrCl > 95</td>
    <td>N/A</td>
    <td>Best studied option in renal dysfunction</td>
    <td>At least 48hrs</td>
  </tr>
</table>


## Additional Information
-	VA is starting to move towards rivaroxaban and apixaban for extended secondary thromboprophylaxis
    -	Write in your PADR for apixaban citing “pt uses a pillbox and cannot use dabigatran”
-	Renal dysfunction: favor warfarin, apixaban or edoxaban
-	Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have higher risk of GI bleed)
-	Pregnancy: UFH/LMWH (other agents may cross the placenta)
-	BMI >40: Apixaban or rivaroxaban can be used per 2016 ISTH guidelines (but avoid dabigatran) 
-	GI malabsorption (e.g. Crohn's): Caution with DOACs, consider enoxaparin 

## Transitioning between Anticoagulants with DOACs

<table border="1">
  <tr>
    <th>From</th>
    <th>To</th>
    <th>Timing</th>
  </tr>
  <tr>
    <td>DOAC</td>
    <td>Warfarin</td>
    <td>
      Low-moderate risk DVT/PE: start warfarin while pt is on DOAC, stop DOAC on day 3 of warfarin therapy, and check INR on day 4<br><br>
      High risk DVT/PE: start LMWH or UFH, then start warfarin
    </td>
  </tr>
  <tr>
    <td>DOAC</td>
    <td>LMWH</td>
    <td>Stop DOAC and start LMWH when due for next DOAC dose</td>
  </tr>
  <tr>
    <td>DOAC</td>
    <td>UFH</td>
    <td>Start IV heparin with bolus when next DOAC dose is due</td>
  </tr>
  <tr>
    <td>LMWH</td>
    <td>Warfarin</td>
    <td>LMWH and warfarin given simultaneously until INR is therapeutic for 24h</td>
  </tr>
  <tr>
    <td>LMWH</td>
    <td>DOAC</td>
    <td>Stop LMWH and start DOAC when due for next dose of LMWH (within 2h)</td>
  </tr>
  <tr>
    <td>UFH</td>
    <td>DOAC</td>
    <td>Start DOAC when IV stopped (30min prior to cessation if high risk for thrombosis)</td>
  </tr>
  <tr>
    <td>Warfarin</td>
    <td>DOAC</td>
    <td>Start DOAC when INR &lt; 2.0</td>
  </tr>
</table>

## Peri-procedural Management of Anticoagulation
-	Temporary IVC filter indicated in pts with very recent acute VTE (within 3-4 weeks) if the procedure requires AC delay >12 hours
-	For those at high risk of thromboembolism
    -	Consider continuing AC for low-bleeding-risk procedures like dental procedures, cutaneous biopsy/excision, ICD placement, and endovascular procedures.
    -	Can bridge with LMWH or heparin drip

<table border="1">
  <tr>
    <th></th><th>Stop before procedure</th>
    <th>Restart after procedure</th>
  </tr>
  <tr>
    <td>Warfarin</td>
    <td>5 days prior, check INR day of</td>
    <td>12 to 24 hours after</td>
  </tr>
  <tr>
    <td>Dabigatran</td>
    <td rowspan='4'>48 hours prior (longer if CrCl 30-50 or procedure is high bleeding risk)</td>
    <td rowspan='4'>1 day after (2 days if high bleeding risk)</td>
  </tr>
  <tr>
    <td>Rivaroxaban</td>
  </tr>
  <tr>
    <td>Apixaban</td>
  </tr>
  <tr>
    <td>Edoxaban</td>
  </tr>
  <tr>
    <td>Heparin</td>
    <td>Stop infusion 4-5 hours prior</td>
    <td>24 hours after</td>
  </tr>
  <tr>
    <td>Enoxaparin</td>
    <td>12 - 24 hours prior</td>
    <td>24 hours after (48-72 hours if high bleeding risk)</td>
  </tr>
</table>

## Strategies for Reversal of Anticoagulation

### Warfarin
-	Vitamin K: onset within a few hours but takes 24-48 hrs for full effect
    -	Life threatening bleeding: Give IV Vitamin K 10 mg over 30 minutes.
    -	Intracranial bleed, bleed with hemodynamic instability, emergent procedure non-life threatening
        -	INR <5: Vitamin K not recommended
        -	INR 5-10: Vitamin K 1-5 mg IV or PO
        -	INR >10: Vitamin K 5mg PO or 5 mg IV
    -	Prior to surgery
    -	Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to procedure) 
-	FFP: 15 ml/kg (e.g. 4 units/70 kg person) if need reversal <24 hrs, plus give Vitamin K 
-	KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C, Protein S, and heparin
    -	Given instead of plasma when insufficient time for plasma/Vit K to work (i.e. for life threatening hemorrhage)
    -	Avoid giving in HIT
    -	Administer with Vitamin K

### Dabigatran
-	Idarucizumab ($$$) will reverse if prolonged thrombin time (remember to check): Consult Hematology

### Factor Xa inhibitors: rivaroxaban, apixaban, edoxaban
-	FEIBA (Factor VIII inhibitor bypassing activity): can promote coagulation but is NOT a reversal agent; limited data to support use
-	Consult Hematology before using; andexanet alfa (FDA approved) is not on VUMC formulary but is on the VA formulary
